# OnCo record nct02734004 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02734004/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02734004", "NCT02734004" ;
  schema:name "A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors."@en ;
  schema:alternateName "MEDIOLA"@en ;
  schema:description "A phase 1/2 trial of Olaparib and Bevacizumab in ovarian cancer, small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02734004/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02734004> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2016-03-17" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/gastric/> ;
  onco:technologies <https://onco.cc/technologies/parp-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/iqvia/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct02734004-lancet-oncol-2020/> .